LivaNova, PLC announced that a data presentation on the Perceval sutureless valve was unveiled at The Society of Thoracic Surgeons 53rd Annual Meeting (STS), which took place January 21-25, 2017 in Houston. These data highlight the safety, efficiency, and performance of Perceval, the first-ever, truly sutureless surgical valve designed for patients requiring an aortic valve replacement (AVR). The study, Aortic Valve Replacement With Sutureless Perceval Bioprosthesis: Single-Center Experience With 617 Implants, analyzed patients who underwent AVR with the Perceval bioprosthesis. The study found that AVR procedures conducted with Perceval resulted in low mortality and excellent hemodynamic performance for patients. The study found that Perceval, with its safe and reproducible features, allowed surgeons to employ a minimally invasive approach during AVR procedures. At follow-up at approximately 16 months, freedom from reoperation was 99% and patient survival was 91.3%. Perceval has been implanted in more than 20,000 patients in over 310 hospitals in 34 countries across the world.